Featured

Gene-editing Therapy CTX-001 Granted Priority Medicines Designation for Severe SCD in EU
News

Gene-editing Therapy CTX-001 Granted Priority Medicines Designation for Severe SCD in EU

CTX001, an investigational gene-editing cell therapy, has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of severe sickle cell disease (SCD). The announcement was made by CRISPR Therapeutics and Vertex Pharmaceuticals, which are jointly…
COVID-19 Update: Here’s Where We Stand Now In the Race For A Vaccine
Clinical News

COVID-19 Update: Here’s Where We Stand Now In the Race For A Vaccine

As large parts of the world prepare for a second wave of coronavirus cases governments have pinned their hopes on the rapid development of a vaccine to provide a route…
TIF’s Latest Newsletter Issue Is Out!
News

TIF’s Latest Newsletter Issue Is Out!

Our August 2020 newsletter has just been published! Read about our latest updates, including country activities, international projects, educational updates for patients with thalassaemia and haemoglobin disorders, and our novel…
Revisiting The Use and Management of Blood in Europe in Times of Crisis and Beyond
News

Revisiting The Use and Management of Blood in Europe in Times of Crisis and Beyond

About 25 million blood transfusions are administered to patients every year throughout the European Union. What may come to mind to most people when thinking about blood transfusion is acute…
AstraZeneca Resumes Final Stage Trials For Its Covid-19 vaccine After Initial Halt
Clinical News

AstraZeneca Resumes Final Stage Trials For Its Covid-19 vaccine After Initial Halt

AstraZeneca Plc and the University of Oxford have resumed the British clinical trials of its Covid-19 vaccine, after the initial suspension over concerns with a participant who fell ill. University…
The ”International Blood Diseases Symposium” Is Just Around The Corner
Member News

The ”International Blood Diseases Symposium” Is Just Around The Corner

The Turkish Federation of Blood Diseases, Kan Hastalıkları Federasyonu  is joining forces with TIF for the organisation of the ”International Blood Diseases Virtual Symposium”, which will be held virtually on…
Coming Up: A TIF Live Webinar on ”Heart Disease in Thalassaemia”
News

Coming Up: A TIF Live Webinar on ”Heart Disease in Thalassaemia”

Tune in with TIF on Tuesday, 15 September 2020, 15:00 EEST, for one of the last webinars from the TIF eThalED series for Healthcare Professionals! The topic to be brought…
AstraZeneca Puts Leading COVID-19 Vaccine Trial On Hold
Clinical News

AstraZeneca Puts Leading COVID-19 Vaccine Trial On Hold

The pharmaceutical company AstraZeneca halted large, late-stage global trials of its coronavirus vaccine on Tuesday, because of a serious suspected adverse reaction in a participant. It is not yet known…
AstraZeneca Starts U.S. Final-Stage Trial of Covid-19 Vaccine
Clinical News

AstraZeneca Starts U.S. Final-Stage Trial of Covid-19 Vaccine

AstraZeneca Plc has begun final-stage, Phase III trial of its coronavirus vaccine AZD1222 in the U.S., according to the company´s latest statement. Trial centers across the US are recruiting up to 30,000 adults aged 18 years…
Back to top button